EUCTR2006-004716-48-AT进行中（未招募）不适用
Effects of agomelatine (25 to 50 mg/day) on sleep EEG parameters compared to escitalopram in patients with Major Depressive Disorder.A 6-week randomised, double-blind parallel groups study versus comparator, followed by a double-blind optional treatment extension period up to 6 months.
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 130
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Outpatients of both genders,
- •- Aged between 18 and 60 years,
- •- Fulfilling DSM-IV-TR criteria for Major Depressive Disorder
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •- Women of childbearing potential without effective contraception,
- •- Positive plasma beta hCG for women
- •- All types of depression other than Major Depressive Disorder,
- •- Contraindication to escitalopram.
研究者
相似试验
进行中（未招募）
不适用
Effects of agomelatine (25 to 50 mg/day) on sleep EEG parameters compared to escitalopram in patients with Major Depressive Disorder.A 6-week randomised, double-blind parallel groups study versus comparator, followed by a double-blind optional treatment extension period up to 6 months.MedDRA version: 8.1Level: LLTClassification code 10057840Term: Major depressionMajor Depressive DisorderEUCTR2006-004716-48-GBInstitut de Recherches Internationales Servier130
进行中（未招募）
1 期
Effects of agomelatine (25 to 50 mg/day) on sleep EEG parameters compared to escitalopram in patients with Major Depressive Disorder.A 6-week randomised, double-blind parallel groups study versus comparator, followed by a double-blind optional treatment extension period up to 6 months.MedDRA version: 8.1Level: LLTClassification code 10057840Term: Major depressionMajor Depressive DisorderEUCTR2006-004716-48-FRInstitut de Recherches Internationales Servier130
进行中（未招募）
不适用
Effects of agomelatine (25 to 50 mg/day) on sleep EEG parameters compared to escitalopram in patients with Major Depressive Disorder.A 6-week randomised, double-blind parallel groups study versus comparator, followed by a double-blind optional treatment extension period up to 6 months.Major Depressive DisorderEUCTR2006-004716-48-FIInstitut de Recherches Internationales Servier130
进行中（未招募）
1 期
Effects of agomelatine (25 to 50 mg/day) on sleep EEG parameters compared to escitalopram in patients with Major Depressive Disorder.A 6-week randomised, double-blind parallel groups study versus comparator, followed by a double-blind optional treatment extension period up to 6 months.Efecto de agomelatina (25 a 50 mg/día) sobre los parámetros electroencefalográficos del sueño comparado con escitalopram en pacientes con Trastorno Depresivo Mayor.Estudio aleatorizado doble ciego, en grupos paralelos frente a comparador durante 6 semanas, seguido de un periodo de extensión opcional doble ciego hasta un total de 6 meses de duración.Major Depressive DisorderTrastorno Depresivo MayorMedDRA version: 8.1Level: LLTClassification code 10057840Term: Major depressionEUCTR2006-004716-48-ESInstitut de Recherches Internationales Servier130
Enrolling By Invitation
不适用
The effect of agomelatine on sleep disturbance, depression and anxiety in patients with systemic lupus erythematosus, a randomized, double-blinded, placebo-controlled trialSLEsleep disturbanceslesleep disturbanceTCTR20171010002/A72